Acorda Therapeutics Insider Jane Wasman Sells 3,750 Shares (ACOR)
Acorda Therapeutics (NASDAQ:ACOR) Insider Jane Wasman sold 3,750 shares of the stock on the open market in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $35.74, for a total transaction of $134,025.00. Following the sale, the insider now directly owns 105,459 shares of the company’s stock, valued at approximately $3,769,105. The sale was disclosed in a document filed with the SEC, which is available at this link.
Acorda Therapeutics (NASDAQ:ACOR) traded down 1.01% during mid-day trading on Monday, hitting $36.17. 44,121 shares of the company’s stock traded hands. Acorda Therapeutics has a 52-week low of $22.37 and a 52-week high of $40.87. The stock’s 50-day moving average is $35.25 and its 200-day moving average is $34.88. The company has a market cap of $1.448 billion and a P/E ratio of 10.28.
Acorda Therapeutics (NASDAQ:ACOR) last announced its earnings results on Thursday, August 1st. The company reported $0.25 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.09 by $0.16. The company had revenue of $87.05 million for the quarter, compared to the consensus estimate of $82.57 million. During the same quarter in the prior year, the company posted $0.27 earnings per share. The company’s quarterly revenue was up 15.1% on a year-over-year basis. On average, analysts predict that Acorda Therapeutics will post $0.27 earnings per share for the current fiscal year.
ACOR has been the subject of a number of recent research reports. Analysts at Aegis raised their price target on shares of Acorda Therapeutics from $43.00 to $50.00 in a research note to investors on Tuesday, October 1st. They now have a “buy” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Acorda Therapeutics in a research note to investors on Friday, September 6th. They now have a $38.00 price target on the stock. Finally, analysts at Cowen and Company raised their price target on shares of Acorda Therapeutics from $37.73 to $50.00 in a research note to investors on Friday, August 2nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $42.67.
Acorda Therapeutics, Inc (NASDAQ:ACOR) is a commercial-stage biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.